Ipsen Consumer Healthcare rises as review progresses

Ipsen Consumer Healthcare rises as review progresses
Ipsen’s chief executive officer David Loew announced in December 2020 that the company’s Consumer Healthcare business was “non-core”

25 October 2021 - Deborah Wilkes

  • Ipsen’s review of Consumer Healthcare business continues
  • Consumer Healthcare’s sales rise for second quarter in a row
  • Sales up by 12.2% at constant currencies in third quarter of 2021

Ipsen Consumer Healthcare posted sales up by 12.2% at constant currencies in the third quarter of 2021 as the strategic review of the business continued.

Ipsen’s chief executive officer David Loew said the strategic review was “progressing” but did not provide an update.

Loew announced in December 2020 that Consumer Healthcare was “non-core” (click here to read the News story).

In the third quarter of 2021, the Consumer Healthcare business recorded sales of EUR59.6 million (USD69.0 million), representing a rise of 12.2% at constant currencies compared to the same period a year earlier. As reported, sales were up by 12.8%.

The growth followed a rise of 23.1% at constant currencies in the second quarter of 2021 (click here to read the News story). However, sales fell by 5.4% in the first quarter of 2021 (click here to read the News story) and by 21.3% in the whole of 2020 (click here to read the News story).

For the first nine months of 2021, Ipsen Consumer Healthcare reported sales up by 9.8% at constant currencies to EUR166 million. As reported, sales were up by 7.5%.

In the same period a year earlier, Ipsen Consumer Healthcare’s sales were down by 21.4% at constant currencies to EUR154 million (click here to read the News story).

Commenting on the latest results, Ipsen said growth reflected the “performance of Smecta (diosmectite) and the strong COVID-19 recovery”.

Performance by product

As can be seen from Figure 1 below, Consumer Healthcare's biggest seller in the first nine months of 2021 was the gastrointestinal product Smecta, with sales up by 11.9% at constant currencies to EUR63.5 million. Ipsen said growth had been driven by “the COVID-19 recovery in China and Russia”.

Figure 1: Worldwide sales by Ipsen’s Consumer Healthcare business in the first nine months of 2021, broken down by product. Change in sales is compared to the first nine months of 2020. *CER is at constant exchange rates (Source – Ipsen/OTCToolbox)

 

The Tanakan ginkgo biloba product recorded sales up by 8.7% at constant currencies to EUR27.9 million. Ipsen said the rise had been driven by the “performance and a high level of deliveries in Vietnam”.

Sales of the third-largest product – Fortrans/Eziclen (macrogol 4000) – increased by 40.6% at constant currencies to EUR26.0 million. Ipsen said the rise reflected the recovery in China.

Sales of the Forlax laxative were down by 12.9% at constant currencies to EUR25.8 million.

Sales of Other Consumer Healthcare products increased by 10.7% to EUR22.2 million at constant currencies.

The business accounted for 8.0% of French pharmaceutical company Ipsen’s total sales in the first nine months of 2021 which were up by 12.3% at constant currencies to EUR2.08 billion. Sales as reported were up by 9.3%.

Click tags below for more information on topics:

Ipsen

Back to Industry News

Share this page: